SCHEMBL24315872

SCHEMBL24315872

CN1CCN(c2ccc3c4c(ccnc24)N(C2CCC(=O)NC2=O)C3=O)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 18/20 0.56
DDB1 Q16531 11/20 0.46
IKZF3 Q9UKT9 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CHRM2 P08172 1/20 0.46
OPRM1 P35372 1/20 0.46
CYP1A2 P05177 1/20 0.46
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TNF P01375 1/20 0.42
IL1B P01584 1/20 0.42
TBXA2R P21731 1/20 0.42
IKZF1 Q13422 1/20 0.42
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24315760 0.85 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315747 0.84 CRBN (0.47) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL26664926 0.83 MEN1 (0.39) CRBNMEN1USP2LMNAGAA
SCHEMBL24315815 0.83 CRBN (0.47) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315768 0.82 CRBN (0.47) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24317674 0.82 CRBN (0.54) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315960 0.82 CRBN (0.58) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29532388 0.82 CRBN (0.58) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24315769 0.82 CRBN (0.45) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24317607 0.81 CRBN (0.51) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 CRBN 50/4885DDB1 215/4885IKZF3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.